# Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK

> **NCT05164393** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Coegin Pharma AB** · enrollment: 60 (estimated)

## Conditions studied

- Actinic Keratoses

## Interventions

- **DRUG:** AVX001

## Key facts

- **NCT ID:** NCT05164393
- **Lead sponsor:** Coegin Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-02
- **Primary completion:** 2022-03
- **Final completion:** 2022-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164393, "Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05164393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*